[HTML][HTML] Glycogen synthase kinase-3 signaling in Alzheimer's disease

E Lauretti, O Dincer, D Praticò - … et Biophysica Acta (BBA)-Molecular Cell …, 2020 - Elsevier
Alzheimer's disease (AD) is the most common form of neurodegenerative disorder with
dementia, accounting for approximately 70% of the all cases. Currently, 5.8 million people in …

Therapeutic strategies for Alzheimer's disease in clinical trials

J Godyń, J Jończyk, D Panek, B Malawska - Pharmacological Reports, 2016 - Elsevier
Alzheimer's disease (AD) is considered to be the most common cause of dementia and is an
incurable, progressive neurodegenerative disorder. Current treatment of the disease …

Diet in the prevention of Alzheimer's disease: current knowledge and future research requirements

O Stefaniak, M Dobrzyńska, S Drzymała-Czyż… - Nutrients, 2022 - mdpi.com
Alzheimer's disease is a progressive brain disease that is becoming a major health problem
in today's world due to the aging population. Despite it being widely known that diet has a …

Alzheimer's disease: a review from the pathophysiology to diagnosis, new perspectives for pharmacological treatment

P dos Santos, C Leide, PF Ozela… - Current medicinal …, 2018 - ingentaconnect.com
Dementia is characterized by the impairment of cognition and behavior of people over 65
years. Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder in the …

Aging microglia—phenotypes, functions and implications for age-related neurodegenerative diseases

B Spittau - Frontiers in aging neuroscience, 2017 - frontiersin.org
Aging of the central nervous system (CNS) is one of the major risk factors for the
development of neurodegenerative pathologies such as Parkinson's disease (PD) and …

Dietary patterns and Alzheimer's disease: an updated review linking nutrition to neuroscience

I Ellouze, J Sheffler, R Nagpal, B Arjmandi - Nutrients, 2023 - mdpi.com
Alzheimer's disease (AD) is a growing concern for the aging population worldwide. With no
current cure or reliable treatments available for AD, prevention is an important and growing …

PSEN1ΔE9, APPswe, and APOE4 confer disparate phenotypes in human iPSC-derived microglia

H Konttinen, S Ohtonen, S Wojciechowski… - Stem cell reports, 2019 - cell.com
Here we elucidate the effect of Alzheimer disease (AD)-predisposing genetic backgrounds,
APOE4, PSEN1ΔE9, and APPswe, on functionality of human microglia-like cells (iMGLs) …

Protective effect of amyloid-β peptides against herpes simplex virus-1 infection in a neuronal cell culture model

K Bourgade, A Le Page, C Bocti… - Journal of …, 2016 - content.iospress.com
Senile amyloid plaques are one of the main hallmarks of Alzheimer's disease (AD). They
correspond to insoluble deposits of amyloid-ß peptides (Aß) and are responsible for the …

Revisiting the blood-brain barrier: A hard nut to crack in the transportation of drug molecules

S Harilal, J Jose, R Kumar, MK Unnikrishnan… - Brain research …, 2020 - Elsevier
Barriers are the hallmark of a healthy physiology, blood-brain barrier (BBB) being a tough
nut to crack for most of the antigens and chemical substances. The presence of tight …

Mutations in presenilin 2 and its implications in Alzheimer's disease and other dementia-associated disorders

Y Cai, SSA An, SY Kim - Clinical interventions in aging, 2015 - Taylor & Francis
Alzheimer's disease (AD) is the most common form of dementia. Mutations in the genes
encoding presenilin 1 (PSEN1), presenilin 2 (PSEN2), and amyloid precursor protein have …